Barbara Kosacz - 04 Jan 2024 Form 4 Insider Report for Kronos Bio, Inc. (KRON)

Reporting relationship: COO & General Counsel
Issuer ticker: KRON
Reported as of: 04 Jan 2024
Net transaction value: -$12,636
SEC form: 4
Accepted by SEC: 05 Jan 2024, 18:26:51 UTC
Prior SEC filing: 22 May 2023
Next SEC filing: 16 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Allison Frisbee, Attorney-in-Fact

Key filing fact

Barbara Kosacz filed Form 4 for Kronos Bio, Inc. (KRON) on 05 Jan 2024.

Key facts

This page summarizes Barbara Kosacz's Form 4 filing for Kronos Bio, Inc. (KRON).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2024, 18:26.

Change

Previous filing in this sequence was filed on 22 May 2023.
Current net transaction value: -$12,636.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KRON transaction

Common Stock

Sale

Transaction value: $12,636
Shares: -10,676
Change %: -1.1%
Price: $1.18
Shares after: 928,966
Date: 04 Jan 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units.

Footnote F2

The weighted average sale price for the transaction reported was $1.1836, and the range of prices were between $1.12 to $1.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.